Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of PROCTOeze® PLUS

Inclusion Criteria: * Men and women ≥ 18 years old. * Patients diagnosed with Grade I - II symptomatic haemorrhoids (according to Goligher classification) confirmed by clinical and anoscopic or proctoscopic examination performed within 3 months before baseline. * Patients able to do self-administration at home of the MD, for 14 days, to treat symptoms of haemorrhoids and anal irritation. * Patient free from the following treatments for haemorrhoids for at least 4 weeks: laser treatments for haemorrhoids, steroidal or non-steroidal anti-inflammatory drugs, analgesics, any anti-haemorrhoidal treatment, anticoagulants, and antiplatelet agents. * Patients able to communicate adequately with the Investigator and understand the tral questionnaire. * Patients able to understand and who can provide valid informed consent to the trial. Exclusion Criteria: * Inflammatory and infectious disease of the digestive tract (e.g., IBD - Inflammatory Bowel Disease). * Frequent hemorraidal bleeding * Severe, uncontrolled hypertension, renal failure, cirrhosis, colorectal cancer, anal fissure or fistula. * Patients with known sensitivity to the tested medical device or its components. * Patients with any other medical condition that, in the opinion of the Investigator, would compromise participation or be likely to lead to hospitalisation during the study. * Participation in an interventional clinical study or administration of any investigational agents in the previous 30 days.